ImmunoGen Stock Price, News & Analysis (NASDAQ:IMGN)

$6.70 -0.09 (-1.33 %)
(As of 12/15/2017 04:57 AM ET)
Previous Close$6.79
Today's Range$6.61 - $6.95
52-Week Range$1.53 - $8.84
Volume3.15 million shs
Average Volume2.87 million shs
Market Capitalization$801.43 million
P/E RatioN/A
Dividend YieldN/A
Beta2.2

About ImmunoGen (NASDAQ:IMGN)

ImmunoGen logoImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.

Receive IMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IMGN
CUSIP45253H10
Phone781-895-0600

Debt

Debt-to-Equity Ratio-0.03%
Current Ratio2.81%
Quick Ratio2.78%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$60 million
Price / Sales14.77
Cash FlowN/A
Price / CashN/A
Book Value($0.19) per share
Price / Book-35.26

Profitability

Trailing EPS($1.30)
Net Income$-143,650,000.00
Net Margins-130.00%
Return on EquityN/A
Return on Assets-49.89%

Miscellaneous

Employees385
Outstanding Shares132,250,000

ImmunoGen (NASDAQ:IMGN) Frequently Asked Questions

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) released its earnings results on Friday, November, 3rd. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.42. The biotechnology company had revenue of $8.50 million for the quarter, compared to the consensus estimate of $26.09 million. The company's revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.51) EPS. View ImmunoGen's Earnings History.

Where is ImmunoGen's stock going? Where will ImmunoGen's stock price be in 2017?

8 brokers have issued 12 month price targets for ImmunoGen's stock. Their predictions range from $1.30 to $12.00. On average, they anticipate ImmunoGen's stock price to reach $8.05 in the next year. View Analyst Ratings for ImmunoGen.

What are Wall Street analysts saying about ImmunoGen stock?

Here are some recent quotes from research analysts about ImmunoGen stock:

  • 1. Cantor Fitzgerald analysts commented, "FORWARD Progress. The nearest term commercial opportunity for IMGN is the FORWARD I trial, which is exploring mirvetuximab soravtansine (mirva") as a single agent in 3rd line ovarian cancer in women who express high levels of the FRa receptor. This trial could read out in 2019 pending completion of enrollment in 2018." (11/3/2017)
  • 2. According to Zacks Investment Research, "ImmunoGen has made a significant progress with regard to its lead pipeline candidate, mirvetuximab soravtansine (platinum-resistant ovarian cancer). Successful development and subsequent approval will be a huge boost for the company as ovarian cancer market represents a huge potential. The company’s collaborations with big healthcare companies not only validate its technology but also provides it with funds in the form of milestone and royalty payments. The company’s shares have outperformed the broader industry so far this year. However, ImmunoGen is heavily dependent on its lead candidate, mirvetuximab soravtansine. Hence, any kind of development or regulatory setback could hamper the stock. Most other pipeline candidates are still a long way from entering the market, which also raises concern. Estimates have been stable lately ahead of the company's Q3 earnings." (10/31/2017)
  • 3. Cowen Inc analysts commented, "IMGN announced a collaboration agreement with Jazz for the development and." (8/29/2017)

Are investors shorting ImmunoGen?

ImmunoGen saw a increase in short interest in the month of November. As of November 30th, there was short interest totalling 13,085,450 shares, an increase of 13.8% from the November 15th total of 11,501,652 shares. Based on an average daily trading volume, of 2,418,778 shares, the short-interest ratio is currently 5.4 days. Currently, 10.1% of the company's stock are short sold.

Who are some of ImmunoGen's key competitors?

Who are ImmunoGen's key executives?

ImmunoGen's management team includes the folowing people:

  • Stephen C. McCluski, Independent Chairman of the Board (Age 64)
  • Mark J. Enyedy, President, Chief Executive Officer, Director (Age 53)
  • David B. Johnston PhD, Chief Financial Officer, Executive Vice President (Age 61)
  • Richard J. Gregory Ph.D., Executive Vice President - Research, Chief Scientific Officer (Age 59)
  • Craig Barrows, Executive Vice President, General Counsel, Secretary (Age 62)
  • Anna Berkenblit M.D., Vice President and Chief Medical Officer (Age 47)
  • Theresa G. Wingrove Ph.D., Vice President - Regulatory Affairs and Quality (Age 59)
  • Peter J. Williams, Vice President - Business Development (Age 62)
  • Mark A. Goldberg M.D., Independent Director (Age 62)
  • Dean Jonathan Mitchell, Independent Director (Age 61)

Who owns ImmunoGen stock?

ImmunoGen's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (5.24%), Wells Fargo & Company MN (1.47%), Pinnacle Associates Ltd. (1.41%), Bank of New York Mellon Corp (0.53%), Chicago Equity Partners LLC (0.55%) and Schwab Charles Investment Management Inc. (0.42%). Company insiders that own ImmunoGen stock include Craig Barrows, Daniel M Junius, John Lambert, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.

Who sold ImmunoGen stock? Who is selling ImmunoGen stock?

ImmunoGen's stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Neuberger Berman Group LLC, Pinnacle Associates Ltd., Wells Fargo & Company MN, Bank of New York Mellon Corp, Russell Investments Group Ltd., GSA Capital Partners LLP and California State Teachers Retirement System. View Insider Buying and Selling for ImmunoGen.

Who bought ImmunoGen stock? Who is buying ImmunoGen stock?

ImmunoGen's stock was purchased by a variety of institutional investors in the last quarter, including Chicago Equity Partners LLC, Allianz Asset Management GmbH, David R. Rahn & Associates Inc., Schwab Charles Investment Management Inc., Trexquant Investment LP, Perceptive Advisors LLC, Dynamic Technology Lab Private Ltd and TD Asset Management Inc.. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

How do I buy ImmunoGen stock?

Shares of ImmunoGen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ImmunoGen's stock price today?

One share of ImmunoGen stock can currently be purchased for approximately $6.70.

How big of a company is ImmunoGen?

ImmunoGen has a market capitalization of $801.43 million and generates $60 million in revenue each year. The biotechnology company earns $-143,650,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. ImmunoGen employs 385 workers across the globe.

How can I contact ImmunoGen?

ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-895-0600 or via email at [email protected]


MarketBeat Community Rating for ImmunoGen (IMGN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  251 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  516
MarketBeat's community ratings are surveys of what our community members think about ImmunoGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ImmunoGen (NASDAQ:IMGN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.442.442.442.33
Ratings Breakdown: 1 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.61$7.61$7.73$5.09
Price Target Upside: 56.03% upside56.03% upside1.91% upside2.16% upside

ImmunoGen (NASDAQ:IMGN) Consensus Price Target History

Price Target History for ImmunoGen (NASDAQ:IMGN)

ImmunoGen (NASDAQ:IMGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2017Cantor FitzgeraldReiterated RatingHold$5.00N/AView Rating Details
10/12/2017Jefferies GroupReiterated RatingBuy$9.00N/AView Rating Details
8/30/2017Canaccord GenuityReiterated RatingBuy$8.00 -> $10.00MediumView Rating Details
8/29/2017CowenReiterated RatingHoldHighView Rating Details
8/29/2017Leerink SwannReiterated RatingOutperform -> BuyHighView Rating Details
7/6/2017Royal Bank of CanadaUpgradeSector Perform -> Outperform$5.00 -> $12.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
3/1/2017Morgan StanleyLower Price TargetUnderweight$2.50 -> $1.30N/AView Rating Details
8/5/2016J P Morgan Chase & CoSet Price TargetHold$9.00 -> $5.00N/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

ImmunoGen (NASDAQ:IMGN) Earnings History and Estimates Chart

Earnings by Quarter for ImmunoGen (NASDAQ:IMGN)

ImmunoGen (NASDAQ IMGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2017Q3 2017($0.19)($0.61)$26.09 million$8.50 millionViewN/AView Earnings Details
7/28/2017Q2 2017($0.17)($0.10)$30.59 million$39.02 millionViewN/AView Earnings Details
5/5/20173/31/2017($0.36)($0.20)$16.16 million$28.70 millionViewN/AView Earnings Details
2/17/2017Q2 2017($0.39)($0.39)$16.28 million$13.85 millionViewListenView Earnings Details
10/28/2016Q117($0.38)($0.51)$21.12 million$7.66 millionViewListenView Earnings Details
8/4/2016Q416($0.39)($0.51)$17.11 million$7.41 millionViewListenView Earnings Details
4/29/2016Q316($0.31)($0.37)$23.02 million$19.71 millionViewListenView Earnings Details
1/29/2016Q216($0.36)($0.38)$19.54 million$18.03 millionViewListenView Earnings Details
10/27/2015Q116($0.35)($0.39)$15.84 million$14.90 millionViewListenView Earnings Details
7/31/2015Q415($0.34)($0.35)$15.42 million$12.61 millionViewListenView Earnings Details
4/24/2015Q315($0.25)($0.25)$20.95 million$11.40 millionViewListenView Earnings Details
1/30/2015Q215($0.06)$0.16$37.30 million$48.30 millionViewListenView Earnings Details
10/24/2014Q115($0.14)($0.26)$21.80 million$13.20 millionViewListenView Earnings Details
8/1/2014Q414($0.36)($0.31)$9.72 million$5.74 millionViewN/AView Earnings Details
4/25/2014Q314($0.27)($0.44)$13.28 million$6.90 millionViewN/AView Earnings Details
1/31/2014Q214($0.18)($0.29)$18.16 million$30.10 millionViewListenView Earnings Details
10/25/2013Q114($0.23)($0.13)$12.10 million$17.20 millionViewN/AView Earnings Details
8/2/2013Q4 2013($0.30)($0.26)$3.44 million$3.83 millionViewN/AView Earnings Details
4/26/2013Q3 2013($0.15)($0.02)$11.94 million$25.00 millionViewN/AView Earnings Details
1/25/2013Q2 2013($0.25)($0.29)$6.02 million$2.60 millionViewN/AView Earnings Details
10/26/2012Q113($0.25)($0.30)$4.10 million$4.10 millionViewN/AView Earnings Details
8/3/2012($0.30)($0.29)ViewN/AView Earnings Details
4/27/2012($0.26)($0.24)ViewN/AView Earnings Details
1/27/2012($0.22)($0.17)ViewN/AView Earnings Details
10/27/2011($0.22)($0.26)ViewN/AView Earnings Details
8/3/2011($0.24)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

ImmunoGen (NASDAQ:IMGN) Earnings Estimates

2017 EPS Consensus Estimate: ($0.90)
2018 EPS Consensus Estimate: ($1.04)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.33)($0.33)($0.33)
Q2 20173($0.35)$0.17($0.07)
Q3 20173($0.46)($0.16)($0.34)
Q4 20172($0.22)($0.09)($0.16)
Q1 20181($0.23)($0.23)($0.23)
Q2 20181($0.27)($0.27)($0.27)
Q3 20181($0.27)($0.27)($0.27)
Q4 20181($0.27)($0.27)($0.27)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ImmunoGen (NASDAQ:IMGN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ImmunoGen (NASDAQ IMGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.51%
Institutional Ownership Percentage: 68.02%
Insider Trades by Quarter for ImmunoGen (NASDAQ:IMGN)
Institutional Ownership by Quarter for ImmunoGen (NASDAQ:IMGN)

ImmunoGen (NASDAQ IMGN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Craig BarrowsVPSell37,050$6.81$252,310.50View SEC Filing  
9/13/2017Craig BarrowsVPSell14,600$6.95$101,470.00View SEC Filing  
12/15/2016Mark Alan GoldbergDirectorBuy20,000$1.80$36,000.00View SEC Filing  
11/8/2016Mark J EnyedyCEOBuy25,000$1.83$45,750.00View SEC Filing  
11/2/2016Craig BarrowsInsiderBuy10,000$1.71$17,100.00View SEC Filing  
11/2/2016Richard J GregoryVPBuy16,600$1.78$29,548.00View SEC Filing  
2/1/2016John LambertEVPSell3,889$8.22$31,967.58View SEC Filing  
1/8/2016Richard J GregoryVPSell2,369$11.10$26,295.90View SEC Filing  
1/4/2016Daniel M. JuniusCEOSell5,416$13.17$71,328.72View SEC Filing  
1/4/2016John LambertEVPSell3,889$13.20$51,334.80View SEC Filing  
12/1/2015Daniel M. JuniusCEOSell5,416$13.11$71,003.76View SEC Filing  
12/1/2015John LambertEVPSell3,889$13.11$50,984.79View SEC Filing  
11/27/2015Charles Q MorrisVPSell5,170$14.00$72,380.00View SEC Filing  
11/17/2015Dean J MitchellDirectorBuy10,000$12.51$125,100.00View SEC Filing  
11/2/2015Daniel M. JuniusCEOSell5,497$12.00$65,964.00View SEC Filing  
11/2/2015John LambertEVPSell3,889$11.73$45,617.97View SEC Filing  
10/29/2015Daniel M. JuniusCEOSell5,335$12.01$64,073.35View SEC Filing  
10/1/2015John LambertEVPSell3,889$9.55$37,139.95View SEC Filing  
9/17/2015David Brannon JohnstonCFOSell5,000$15.00$75,000.00View SEC Filing  
9/1/2015Daniel M. JuniusCEOSell5,416$13.15$71,220.40View SEC Filing  
9/1/2015John LambertEVPSell3,889$13.16$51,179.24View SEC Filing  
7/1/2015Daniel M JuniusCEOSell5,416$14.34$77,665.44View SEC Filing  
7/1/2015John LambertEVPSell3,888$14.34$55,753.92View SEC Filing  
6/15/2015Nicole OnettoDirectorSell3,211$13.86$44,504.46View SEC Filing  
6/1/2015John LambertEVPSell15,000$11.78$176,700.00View SEC Filing  
5/7/2015Daniel M JuniusCEOSell1,215$8.02$9,744.30View SEC Filing  
5/1/2015John LambertEVPSell10,000$8.32$83,200.00View SEC Filing  
11/28/2014Charles Q MorrisVPSell5,240$10.40$54,496.00View SEC Filing  
3/17/2014Daniel JuniusCEOSell15,000$16.40$246,000.00View SEC Filing  
2/26/2014Charles MorrisVPSell6,936$17.35$120,339.60View SEC Filing  
2/20/2014Charles MorrisVPSell13,672$17.10$233,791.20View SEC Filing  
2/18/2014Daniel JuniusCEOSell15,000$16.26$243,900.00View SEC Filing  
2/3/2014John LambertEVPSell4,375$14.90$65,187.50View SEC Filing  
1/22/2014Charles MorrisVPSell7,138$17.00$121,346.00View SEC Filing  
1/10/2014Theresa WingroveVPSell6,250$15.04$94,000.00View SEC Filing  
1/2/2014John LambertEVPSell4,375$14.53$63,568.75View SEC Filing  
12/10/2013Daniel JuniusCEOSell15,000$15.11$226,650.00View SEC Filing  
12/2/2013John LambertEVPSell4,375$14.70$64,312.50View SEC Filing  
11/26/2013Charles MorrisVPSell12,500$13.75$171,875.00View SEC Filing  
11/1/2013John LambertEVPSell4,375$16.41$71,793.75View SEC Filing  
9/10/2013Gregory D PerryCFOSell18,337$17.82$326,765.34View SEC Filing  
9/3/2013Daniel JuniusCEOSell16,667$16.43$273,838.81View SEC Filing  
9/3/2013John LambertEVPSell4,375$16.45$71,968.75View SEC Filing  
8/1/2013Daniel M JuniusCEOSell16,667$19.21$320,173.07View SEC Filing  
8/1/2013John LambertEVPSell4,375$19.21$84,043.75View SEC Filing  
7/11/2013James J O'learyVPSell35,000$19.02$665,700.00View SEC Filing  
7/3/2013Daniel M JuniusCEOSell16,667$17.31$288,505.77View SEC Filing  
7/1/2013John LambertEVPSell4,375$16.80$73,500.00View SEC Filing  
6/3/2013John LambertEVPSell11,250$17.20$193,500.00View SEC Filing  
5/24/2013James J O'learyVPSell28,900$18.11$523,379.00View SEC Filing  
5/1/2013John LambertEVPSell11,250$15.56$175,050.00View SEC Filing  
4/11/2013James J O'learyVPSell31,100$17.37$540,207.00View SEC Filing  
11/8/2012Mark Alan GoldbergDirectorBuy3,000$11.27$33,810.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ImmunoGen (NASDAQ IMGN) News Headlines

Source:
DateHeadline
Why ImmunoGen, Inc. Jumped Higher TodayWhy ImmunoGen, Inc. Jumped Higher Today
finance.yahoo.com - December 14 at 8:54 AM
ImmunoGen, Inc. (IMGN) Sees Large Growth in Short InterestImmunoGen, Inc. (IMGN) Sees Large Growth in Short Interest
www.americanbankingnews.com - December 14 at 3:10 AM
ETFs with exposure to ImmunoGen, Inc. : December 13, 2017ETFs with exposure to ImmunoGen, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 3:27 PM
Immunogen (IMGN) Announces New Clinical and Preclinical Data from Ongoing Phase 1 study of IMGN779Immunogen (IMGN) Announces New Clinical and Preclinical Data from Ongoing Phase 1 study of IMGN779
www.streetinsider.com - December 11 at 8:41 AM
ImmunoGen, Inc. breached its 50 day moving average in a Bullish Manner : IMGN-US : December 11, 2017ImmunoGen, Inc. breached its 50 day moving average in a Bullish Manner : IMGN-US : December 11, 2017
finance.yahoo.com - December 11 at 8:41 AM
Was ImmunoGen Inc’s (IMGN) Earnings Growth Better Than Industry?Was ImmunoGen Inc’s (IMGN) Earnings Growth Better Than Industry?
finance.yahoo.com - December 5 at 3:26 PM
ImmunoGen, Inc. breached its 50 day moving average in a Bullish Manner : IMGN-US : December 1, 2017ImmunoGen, Inc. breached its 50 day moving average in a Bullish Manner : IMGN-US : December 1, 2017
finance.yahoo.com - December 1 at 11:45 AM
William Blair Comments on ImmunoGen, Inc.s FY2017 Earnings (IMGN)William Blair Comments on ImmunoGen, Inc.'s FY2017 Earnings (IMGN)
www.americanbankingnews.com - December 1 at 10:27 AM
Analysis: Positioning to Benefit within Office Depot, ImmunoGen, Cedar Realty Trust, Carbo Ceramics, Consolidated Communications, and Catalyst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated ResultsAnalysis: Positioning to Benefit within Office Depot, ImmunoGen, Cedar Realty Trust, Carbo Ceramics, Consolidated Communications, and Catalyst Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - November 30 at 8:53 AM
Why Is ImmunoGen (IMGN) Stock Up More Than 150% This Year?Why Is ImmunoGen (IMGN) Stock Up More Than 150% This Year?
finance.yahoo.com - November 28 at 9:33 AM
ETFs with exposure to ImmunoGen, Inc. : November 27, 2017ETFs with exposure to ImmunoGen, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 5:23 PM
ImmunoGen, Inc. :IMGN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017ImmunoGen, Inc. :IMGN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 21, 2017
finance.yahoo.com - November 21 at 8:02 PM
ImmunoGen, Inc. (IMGN) Given Consensus Recommendation of "Hold" by AnalystsImmunoGen, Inc. (IMGN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 21 at 1:44 AM
$40.55 Million in Sales Expected for ImmunoGen, Inc. (IMGN) This Quarter$40.55 Million in Sales Expected for ImmunoGen, Inc. (IMGN) This Quarter
www.americanbankingnews.com - November 18 at 6:50 AM
ImmunoGen, Inc. Moves ForwardImmunoGen, Inc. Moves Forward
www.fool.com - November 9 at 4:32 PM
FY2017 EPS Estimates for ImmunoGen, Inc. (IMGN) Decreased by AnalystFY2017 EPS Estimates for ImmunoGen, Inc. (IMGN) Decreased by Analyst
www.americanbankingnews.com - November 8 at 12:16 PM
ImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View Up - NasdaqImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View Up - Nasdaq
www.nasdaq.com - November 8 at 10:18 AM
ImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View Up - NasdaqImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View Up - Nasdaq
www.nasdaq.com - November 8 at 10:18 AM
The Big Reason ImmunoGen, Inc. Shed 24% of Its Value in October - Motley FoolThe Big Reason ImmunoGen, Inc. Shed 24% of Its Value in October - Motley Fool
www.fool.com - November 8 at 10:18 AM
The Big Reason ImmunoGen, Inc. Shed 24% of Its Value in OctoberThe Big Reason ImmunoGen, Inc. Shed 24% of Its Value in October
www.fool.com - November 7 at 2:41 PM
ImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View UpImmunoGen (IMGN) Q3 Loss Wider Than Expected, Cash View Up
finance.yahoo.com - November 7 at 4:04 AM
ImmunoGen, Inc. to Post FY2020 Earnings of ($1.42) Per Share, William Blair Forecasts (IMGN)ImmunoGen, Inc. to Post FY2020 Earnings of ($1.42) Per Share, William Blair Forecasts (IMGN)
www.americanbankingnews.com - November 6 at 2:20 PM
ImmunoGen Shares Collapse After Huge Miss on Profits, RevenuesImmunoGen Shares Collapse After Huge Miss on Profits, Revenues
247wallst.com - November 5 at 7:19 PM
Cantor Fitzgerald Reaffirms "Hold" Rating for ImmunoGen, Inc. (IMGN)Cantor Fitzgerald Reaffirms "Hold" Rating for ImmunoGen, Inc. (IMGN)
www.americanbankingnews.com - November 5 at 1:34 PM
ImmunoGen (IMGN) Reports Wider-than-Expected Q3 Loss - NasdaqImmunoGen (IMGN) Reports Wider-than-Expected Q3 Loss - Nasdaq
www.nasdaq.com - November 5 at 2:37 AM
Edited Transcript of IMGN earnings conference call or presentation 3-Nov-17 12:00pm GMTEdited Transcript of IMGN earnings conference call or presentation 3-Nov-17 12:00pm GMT
finance.yahoo.com - November 4 at 2:13 AM
ImmunoGen, Inc. (IMGN) Posts Quarterly  Earnings Results, Misses Expectations By $0.42 EPSImmunoGen, Inc. (IMGN) Posts Quarterly Earnings Results, Misses Expectations By $0.42 EPS
www.americanbankingnews.com - November 3 at 2:52 PM
Immunogen (IMGN) to Present New Data on Novel Antibody-Drug Conjugates at ASHImmunogen (IMGN) to Present New Data on Novel Antibody-Drug Conjugates at ASH
www.streetinsider.com - November 3 at 9:46 AM
In The Spotlight: ImmunoGenIn The Spotlight: ImmunoGen
www.rttnews.com - November 3 at 9:46 AM
Should You Buy ImmunoGen (IMGN) Ahead of Earnings?Should You Buy ImmunoGen (IMGN) Ahead of Earnings?
finance.yahoo.com - November 3 at 9:46 AM
ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating ResultsImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results
finance.yahoo.com - November 3 at 9:46 AM
ImmunoGen reports 3Q lossImmunoGen reports 3Q loss
finance.yahoo.com - November 3 at 9:46 AM
ImmunoGen (IMGN) Reports Wider-than-Expected Q3 LossImmunoGen (IMGN) Reports Wider-than-Expected Q3 Loss
finance.yahoo.com - November 3 at 9:45 AM
ImmunoGen Inc (IMGN): Is Healthcare An Attractive Sector Play?ImmunoGen Inc (IMGN): Is Healthcare An Attractive Sector Play?
finance.yahoo.com - November 3 at 9:45 AM
ImmunoGen Shares Collapsing After Huge Miss on Profits, RevenuesImmunoGen Shares Collapsing After Huge Miss on Profits, Revenues
finance.yahoo.com - November 3 at 9:45 AM
Why ImmunoGen, Inc. Got Burned into ASH Today -- The Motley Fool - Motley FoolWhy ImmunoGen, Inc. Got Burned into ASH Today -- The Motley Fool - Motley Fool
www.fool.com - November 2 at 2:15 AM
ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 59th ASH Annual MeetingImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 59th ASH Annual Meeting
finance.yahoo.com - November 2 at 2:15 AM
Why ImmunoGen, Inc. Got Burned into ASH TodayWhy ImmunoGen, Inc. Got Burned into ASH Today
finance.yahoo.com - November 2 at 2:15 AM
Is a Beat in the Cards for ImmunoGen (IMGN) in Q3 Earnings? - NasdaqIs a Beat in the Cards for ImmunoGen (IMGN) in Q3 Earnings? - Nasdaq
www.nasdaq.com - October 30 at 10:03 PM
Is a Beat in the Cards for ImmunoGen (IMGN) in Q3 Earnings?Is a Beat in the Cards for ImmunoGen (IMGN) in Q3 Earnings?
finance.yahoo.com - October 30 at 10:03 PM
Critical Survey: ImmunoGen (IMGN) vs. Its RivalsCritical Survey: ImmunoGen (IMGN) vs. Its Rivals
www.americanbankingnews.com - October 28 at 5:32 AM
-$0.25 EPS Expected for ImmunoGen, Inc. (IMGN) This Quarter-$0.25 EPS Expected for ImmunoGen, Inc. (IMGN) This Quarter
www.americanbankingnews.com - October 27 at 5:30 AM
ImmunoGen, Inc. (IMGN) to Release Quarterly Earnings on FridayImmunoGen, Inc. (IMGN) to Release Quarterly Earnings on Friday
www.americanbankingnews.com - October 27 at 1:34 AM
ImmunoGen, Inc. (IMGN) Receives Average Rating of "Hold" from AnalystsImmunoGen, Inc. (IMGN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - October 27 at 1:30 AM
Who Owns Most Of ImmunoGen Inc (IMGN)?Who Owns Most Of ImmunoGen Inc (IMGN)?
finance.yahoo.com - October 23 at 7:31 PM
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2017 Financial ResultsImmunoGen Announces Conference Call to Discuss Its Third Quarter 2017 Financial Results
finance.yahoo.com - October 21 at 2:11 AM
ImmunoGen (IMGN) vs. Its Competitors Head to Head SurveyImmunoGen (IMGN) vs. Its Competitors Head to Head Survey
www.americanbankingnews.com - October 20 at 10:30 PM
Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?
finance.yahoo.com - October 20 at 12:07 AM
ImmunoGen to Push Leukemia Candidate into Phase I TrialImmunoGen to Push Leukemia Candidate into Phase I Trial
finance.yahoo.com - October 18 at 1:14 AM
BRIEF-Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is activeBRIEF-Immunogen announces investigational new drug application for IMGN632 for hematological malignancies is active
www.reuters.com - October 17 at 1:39 AM

SEC Filings

ImmunoGen (NASDAQ:IMGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ImmunoGen (NASDAQ:IMGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ImmunoGen (NASDAQ IMGN) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.